Review of experimental AAV9 gene therapy for ovarian dysfunction and reproductive aging
This abstract reviews mechanisms of ovarian decline, limits of current treatments, and why AAV9 gene therapy is considered promising but still experimental, with safety questions unresolved. [1]
Automatic summary · not editorially reviewed
The key findings
Current ovarian treatments offer partial benefit but do not directly correct molecular drivers, according to the review. [1]
AAV9 is described as attractive for broad tropism, long-term transgene expression and evidence of ovarian somatic cell transduction. [1]
AAV9 remains experimental and requires evaluation of biodistribution, immune response, off-target effects, germline safety, embryo development, offspring health and tumorigenic risk. [1]
The source at a glance
- Study type / format
- Review abstract
- Population / context
- Ovarian dysfunction and reproductive aging, described in a review context
- Summary based on
- Study abstract
- Original publication
- September 24, 2026
Ovarian decline mechanisms and treatment limits
The abstract describes ovarian decline through follicular depletion, granulosa cell dysfunction, aneuploidy, spindle assembly defects, mitochondrial and DNA damage, telomere shortening, stromal remodeling and cellular senescence. Current approaches — hormonal therapy, assisted reproductive technologies, platelet-rich plasma, stem cells, extracellular vesicles and mitochondrial-targeted treatments — offer partial benefit but, according to the review, do not directly correct the molecular drivers.
Supporting source [1]
Why AAV9 is considered attractive for ovarian cells
The review presents adeno-associated virus serotype 9 (AAV9) as attractive because of its broad tropism, long-term transgene expression, favorable safety profile and evidence of transduction of ovarian somatic cells, particularly granulosa and interstitial cells. It also covers delivery routes and candidate genes. These are described as review topics, not as demonstrated human treatments.
Supporting source [1]
Experimental status and unresolved safety questions
The abstract states that AAV9 remains experimental and requires rigorous evaluation of biodistribution, immune response, off-target effects, germline safety, embryo development, offspring health and tumorigenic risk. It does not report new experiments, participants, outcomes or effect sizes; it is a review summary.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No study design, sample, follow-up or outcome data are reported, and AAV9 is described as experimental, not an established therapy.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Ullah S, Ullah I, Khalil BSF, Geng Z, Kim J, Lee SE, Wu X, Saeed K, Shah AS, Idrees M, Kong IK. · europepmc.org · September 24, 2026